|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using the new densitometric assay approach, levels of O(6)-methylguanine-DNA methyltransferase were found to be significantly lower in cirrhotic compared to non-cirrhotic liver, with very low values obtained for two individuals who were incidentally found to have small hepatocellular carcinomas at the time of liver transplantation.
|
8878776 |
1996 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also analyzed MGMT expression by immunohistochemical analysis of HCC tissue samples.
|
12478658 |
2003 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These data suggested that MGMT gene silencing in a subset of HCCs was likely caused by epigenetic alteration, such as promoter hypermethylation, and that the promoter hypermethylation silenced the hMLH1 gene in half of the hMLH1-negative tumours.
|
12592365 |
2003 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
These data suggested that MGMT gene silencing in a subset of HCCs was likely caused by epigenetic alteration, such as promoter hypermethylation, and that the promoter hypermethylation silenced the hMLH1 gene in half of the hMLH1-negative tumours.
|
12592365 |
2003 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression status of both MGMT and hMLH1 was a predictive factor for overall survival in patients with HCC (P < 0.001).
|
12619064 |
2003 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
Methylation specific PCR did not detect any methylation of the MGMT promoter in Australian and South African HCCs.
|
17342321 |
2007 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation specific PCR did not detect any methylation of the MGMT promoter in Australian and South African HCCs.
|
17342321 |
2007 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In contrast, the frequency of p16(INK4a), MGMT and p14(ARF) promoter hypermethylation in HCCs was unrelated to HBsAg status.
|
17534893 |
2007 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA promoter methylation frequencies in HCC and matching non-malignant cirrhotic liver, respectively, were as follows: p16(INK4a) (76% vs. 24%), GSTP1 (53% vs. 32%), MGMT (6 vs. 12%), DAP-K (68 vs. 100%) and APC (100 vs. 100%).
|
18351580 |
2008 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation frequencies of the ten genes examined in HCC were 40.0% for p14 ( ARF ), 60.9% for p15 ( INK4b ), 70.4% for p16 ( INK4a ), 34.8% for p73, 70.4% for GSTP1, 64.3% for MGMT, 13.0% for hMLH1, 59.1% for RARbeta, 82.6% for SOCS-1, and 80.9% for OPCML.
|
20112070 |
2010 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Importantly, our analysis revealed an association between alcohol intake and the hypomethylation of MGMT and between hypermethylation of GSTP1 and HBV infection, indicating that hypermethylation of the genes analyzed in HCC tumors exhibits remarkably distinct patterns depending on associated risk factors.
|
21146512 |
2011 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human O6 -methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice.
|
22213062 |
2013 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The combined rate of P14 methylation was 35% (95%CI 24-48%) in HCC tumour tissues and 11% (95%CI 4-27%) in adjacent tissues, whereas the combined rate of MGMT methylation was 15% (95%CI 6-32%) in HCC and 10% (95%CI 4-22%) in adjacent tissues.
|
25169493 |
2014 |